| Species |
Human |
| Protein Construction |
EMMPRIN/CD147 (Ala22-His205)
Accession # NP_940991.1 |
His |
| N-term |
C-term |
|
| Conjugate |
[FITC] |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized EMMPRIN/CD147[FITC], His, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiEMMPRIN Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
21.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 28-40 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD147, also known as extracellular matrix metalloproteinase inducer (EMMPRIN) or basigin, is expressed in a variety of cell types. It is involved in the regulation of extracellular matrix (ECM) remodeling during physiological and pathological processes including wound healing, inflammatory diseases, and cancer. CD147 is a diagnostic and therapeutic target in cancer and inflammatory diseases, either directly or indirectly, by targeting CD147 partners. |
| Synonyms |
Basigin; BSG; CD147; 5F7; M6; OK; TCSF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
